The FDA has approved intranasal etripamil (Cardamyst; Milestone Pharmaceuticals) for the acute treatment of paroxysmal supraventricular tachycardia (PSVT), making it the first self-administered, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback